Christopher Liu
Stock Analyst at Lucid Capital
(3.74)
# 2,019
Out of 4,517 analysts
158
Total ratings
42.7%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Maintained: Buy | $18 → $22 | $18.60 | +18.28% | 2 | Jun 22, 2026 | |
| CRDF Cardiff Oncology | Maintained: Buy | $14 → $4 | $0.8745 | +357.40% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Maintained: Buy | $25 | $6.17 | +305.19% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $25.94 | +92.75% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $5 | $1.66 | +201.20% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $5.46 | +156.41% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $3.08 | +94.81% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye | Initiated Coverage: Buy | $11 | $11.35 | -3.08% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $20.40 | +145.10% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.78 | +350.70% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $13.89 | +43.99% | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $3.58 | +151.40% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.82 | +254.61% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.79 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $37 | $55.68 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $36 | $23.07 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $2.95 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $35.93 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $37.94 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $19.37 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $69 | $123.96 | n/a | 7 | Jan 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.58 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $8.03 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $23.16 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $12.76 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $32.22 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $5.45 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.60 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.476 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $11.16 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.9762 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.011 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Jun 22, 2026
Maintained: Buy
Price Target: $18 → $22
Current: $18.60
Upside: +18.28%
Cardiff Oncology
Jun 5, 2026
Maintained: Buy
Price Target: $14 → $4
Current: $0.8745
Upside: +357.40%
NextCure
Jun 2, 2026
Maintained: Buy
Price Target: $25
Current: $6.17
Upside: +305.19%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $25.94
Upside: +92.75%
Actuate Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.66
Upside: +201.20%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $5.46
Upside: +156.41%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $3.08
Upside: +94.81%
Adlai Nortye
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $11.35
Upside: -3.08%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $20.40
Upside: +145.10%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.78
Upside: +350.70%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $13.89
Upside: +43.99%
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.58
Upside: +151.40%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.82
Upside: +254.61%
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.79
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $19 → $37
Current: $55.68
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $23.07
Upside: n/a
Jan 27, 2025
Maintained: Buy
Price Target: $20
Current: $2.95
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $35.93
Upside: n/a
Feb 20, 2024
Maintained: Buy
Price Target: n/a
Current: $37.94
Upside: n/a
Feb 13, 2024
Maintained: Buy
Price Target: $18
Current: $19.37
Upside: n/a
Jan 8, 2024
Maintained: Hold
Price Target: $69
Current: $123.96
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.58
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $8.03
Upside: n/a
Nov 9, 2023
Maintained: Hold
Price Target: $5
Current: $23.16
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $12.76
Upside: n/a
Aug 2, 2018
Rated: Hold
Price Target: n/a
Current: $32.22
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $5.45
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $25.60
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.476
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $11.16
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.9762
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.011
Upside: n/a